


Renumathy Dhanasekaran

 300 Pasteur Drive, Alway M211
Stanford, CA, 94304

 renumathyd@gmail.com

 <http://web.stanford.edu/people/rdhanasekaran>

 twitter.com/renumathyd

NARRATIVE

I am an Assistant Professor in the Division of Gastroenterology and Hepatology at School of Medicine, Stanford University. My primary research goal is to explore the molecular biology of liver cancer in order to identify diagnostic and therapeutic targets for liver cancer. I conduct basic and translational research to understand the molecular mechanisms of liver cancer metastasis and dormancy using mouse models of liver cancer. I play an active role in the cancer genome atlas (TCGA) consortium effort to translate the knowledge gained from the study of genomics of liver cancer. I maintain a bio-repository of tissue and blood samples from patients with liver cancer and have developed several patient derived xenograft (PDX) models for preclinical testing. I am currently funded by the NCI K08 career development award.

EDUCATION

10/1998-10/2004	MBBS	Medicine	Bangalore Medical College, India
05/2005-04/2008	MD	Internal Medicine	Madras Medical College, India
06/2019-Present	PhD	Cancer Biology	Stanford University

POSTDOCTORAL TRAINING

07/2009-06/2012	Resident	Internal Medicine	University of Florida, Gainesville, FL
07/2012-06/2015	Fellow	Gastroenterology	Mayo Clinic, Rochester, MN
07/2015-06/2016	Fellow	Transplant Hepatology	Stanford University, Stanford, CA

FACULTY ACADEMIC APPOINTMENTS

07/2016-Present	Instructor	Gastroenterology and Hepatology	Stanford University, Stanford, CA
-----------------	------------	---------------------------------	-----------------------------------

OTHER PROFESSIONAL POSITIONS

07/2008-06/2009 Research Associate Interventional Radiology Emory University, Atlanta, GA

COMMITTEE SERVICE

2014-2016	American Gastroenterology Association (AGA)	Member, Young GI and Trainee Committee
2014-2016	American Gastroenterology Association (AGA)	Member, Practice management and Economics Committee
2015-2018	American Gastroenterology Association (AGA)	Member, Research Advocacy Subcommittee
2016-2017	American Gastroenterology Association (AGA)	Organizer, Regional Practice Skills Workshop
2015-2017	The Cancer Genome Atlas (TCGA)	Member, Liver Cancer Analysis Working Group
2018-Present	The Cancer Genome Atlas (TCGA)	Member, Tumor Molecular Pathology (TMP) Analysis Working Group
2018-Present	American Association of the Study of Liver Diseases (AASLD)	Member, Hepatobiliary Neoplasia Special Interest group (SIG)
2018-Present	American Association of the Study of Liver Diseases (AASLD)	Member, Communication Subcommittee, Hepatobiliary Neoplasia SIG
2015-Present	American Gastroenterology Association (AGA)	Media Spokesperson
2019-Present	Chronic Liver Disease Foundation (CLDF)	Member, HCC Steering Committee
2019-Present	Organ Procurement and Transplantation Network (OPTN)	Member, National Liver Review Board- Hepatocellular carcinoma
2020, 2021	American Gastroenterology Association (AGA)	Chair, Abstract Selection Committee
2020-Present	American Liver Foundation, Northern California Division	Member, Medical Advisory Committee

LEADERSHIP ROLES

2015-2016	Co-Director, Young Delegates Program	American Gastroenterology Association (AGA)
2016-2017	Organizer, Regional Practice Workshop	American Gastroenterology Association (AGA)
2019	Co-Organizer, Liver Cancer Symposium	Stanford University, Ca
2020	Director of Communication, Division of Gastroenterology and Hepatology	Stanford University, Ca
2020-present	Co-Organizer, Research Seminar series	Stanford University, Ca

EDITORIAL ACTIVITIES

2019-Present	Editorial Board Member	Hepatology Hepatoma Research
2015-Present	Associate Editor	BMC Gastroenterology
2015-Present	Ad-Hoc Reviewer (Publons Verified Reviews in Last 12 months n=39, 99th percentile)	Gastroenterology Hepatology Lancet EClinical Medicine Cancer Biology and Therapy Experimental Cell Research American Journal of Gastroenterology Hepatology Communications Plos One Bioengineered Molecular Nuclear Therapeutics Journal of Extracellular Vesicles American Journal of Clinical Oncology BMC Gastroenterology Life Sciences Therapeutic Advanced in Medical Oncology Journal of Vascular and Interventional Radiology ACG Case Reports Journal

HONORS AND AWARDS

2007	B Braun Scholar B Braun Medical Trust Foundation	Awarded for excellence in Post Graduate studies
2008	Dr. Sivarajan Gold Medal Madras Medical College, India	Awarded for academic excellence

2014	Nominated as Manuscript Coordinator for Liver Cancer Project Analysis Working Group. The Cancer Genome Atlas (TCGA)	Based on research competence, communication skills
2014	Young Investigator Travel Bursary EASL HCC Summit	Awarded for excellent scientific quality of abstract
2015	Young Investigator Travel Bursary International Liver Congress, EASL	Awarded for excellent scientific quality of abstract
2015	William H. Summerskill award Mayo Clinic, Rochester	Awarded for outstanding achievement in research by Fellow in an Internal Medicine subspecialty
2015	Nominated for the Edward C. Rosenow II award Mayo Clinic, Rochester	Nominated for outstanding trainee teaching by Fellow in an Internal Medicine subspecialty
2016	Selected to attend Women's Leadership Conference American Gastroenterology Association (AGA)	Selected amongst women with leadership qualifications in Gastroenterology
2018	Selected to attend AGA-AASLD Academic Skills Workshop American Association of the Study of Liver Diseases (AASLD)	Selected as promising early-stage investigator
2018	Selected to attend AASLD-EASL Masterclass American Association of the Study of Liver Diseases (AASLD)	Selected as promising early-stage investigator
2018	Spectrum Research Career Accelerator Program (ReCAP) Scholar Stanford University	Selected as promising early-stage investigator
2019	Nominated to Sigma Xi, The Scientific Research Honor Society Sigma Xi	Noteworthy achievement as an original investigator in a field of pure or applied science

GRANTS AND FUNDING

Current funding:

2018-2023 Functional Proteomic Analysis and Biomarker Identification in a Novel Mouse Model of Metastatic Hepatocellular Carcinoma (HCC)
National Institutes of Health, National Cancer Institute
Role: PI

The major goal of this grant is to analyze dynamic plasma proteomic changes during hepatocellular carcinoma progression to detect functionally relevant proteins which drive metastasis and also identify biomarkers with translational relevance.

2017-2022 Multi-scale Analysis Of Tumor Microenvironment Heterogeneity

National Institutes of Health, National Cancer Institute

Role: Co-Investigator (PI: Dean Felsher)

The major goal of this grant is to analyze dynamic interactions between the host immune cells and the cancer cells in the tumor microenvironment.

Mentored Trainee Grants:

- 2020 Prognostic Role of Tumor-Associated Macrophages in Hepatocellular Carcinoma
Medical Student Research Award, American College of Gastroenterology
Mentor of Nia Adeniji
The goal of this proposal is to determine the role of tumor associated macrophages in predicting clinical outcome in patients with HCC.
Status- Funding Approved
- 2020 Tumor infiltrating lymphocytes (TIL) in Residual Tumors as Predictors of HCC Recurrence.
Medical Student Rotation (MSR), Conquer Cancer Foundation of ASCO
Mentor of Nia Adeniji
The goal of this proposal is to study the role of tumor infiltrating lymphocytes (TIL) in residual tumors as predictors of HCC recurrence.
Status- Funding Approved
- 2020 Deep Immunophenotyping of Immune Responses to COVID-19 in Patients with Liver Cancer
Translational Medicine (TRAM) Student Pilot Grant
Mentor of Nia Adeniji
The goal of the proposal to determine the immune responses to COVID-19 in patients with hepatocellular carcinoma (HCC).
Status- Funding Approved

Past funding:

- 2016-2017 Identifying Proteomic and Glycoproteomic Signatures for Early Detection of Hepatocellular Carcinoma (HCC) in a Transgenic Mouse Model of Metastatic HCC.
Canary Cancer Seed Grant, Stanford University
Role: PI
The goal of this project is to use a mouse model of metastatic liver cancer to identify proteomic biomarkers.
- 2016-2018 Pilot study to Identify Serum Proteomic Signature for Microvascular Invasion in Human Hepatocellular Carcinoma (HCC)
Translational Research and Applied Medicine (TRAM), Stanford University
Role: PI
The goal of this project is to identify biomarkers of vascular invasion in human HCC
- 2017-2018 Gene Signature to Identify Patients with HCC and Predict their Clinical Outcome

Stanford Predictives and Diagnostics Accelerator (SPADA), Stanford University

Role: PI

The goal of this project is to validate the role of a prognostic signature in predicting clinical outcome in patients with HCC.

2017-2018 Circulating Tumor Free DNA (ctDNA) as a Non-invasive Plasma Biomarker for Hepatocellular Carcinoma (HCC)

Apostle Inc

Role: Co-Investigator (PI: Dean Felsher)

The goal of this project is to evaluate the role of ctDNA as a biomarker of HCC using a novel DNA extraction technology.

TEACHING AND TRAINING

2016-2018	Viral hepatitis 2nd year medical students	Stanford Medical School Two 3 hr sessions/ Year
2017-2019	Liver Masses Gastroenterology Fellows	Stanford University One hour Lecture/ Year

MENTORED TRAINEES

2017-2018	Vinodhini Arjunan MBBS/ Resident, Florida Atlantic University Mentoring Role: Research Advisor. Accomplishments: Authored one first- and two co-author manuscripts of the mentored research. Presented 2 abstracts at a national conference.	
2018-Present	Nia Adeniji/ Medical Student, Stanford University Mentoring Role: Research Advisor. Accomplishments: Co-author in a manuscript from the mentored research. Presented abstract at Stanford Research Retreat. Received the ACG Medical student award and Conquer ASCO medical student award under my mentorship.	
2017-Present	Maya Krishnan/ Undergraduate Student, Stanford University Mentoring Role: Research Advisor. Accomplishments: Authored one first- and two co-author manuscripts of the mentored research. Presented oral abstract at National conference. Admitted to MD/PhD program at Indiana University	
2018-Present	Jango Park/Post-Bac Research Assistant, Stanford University Mentoring Role: Research Supervisor. Accomplishments: Currently applying for graduate school. Authored two co-authored manuscripts from the mentored research.	

LOCAL INVITED PRESENTATIONS

- 2017 Pilot study to Identify Serum Proteomic Signature for Microvascular Invasion in Human Hepatocellular Carcinoma (HCC)
Translational Research (TRAM) Symposium, Stanford University, CA
- 2019 Genomics of Liver Cancer
Emmett Keefe Annual Symposium, Stanford University, CA
- 2019 Hepatitis B and Hepatocellular carcinoma
Peter Gregory Symposium, Stanford University, CA
- 2019 Liver Masses and Tumors
GI Board Review, Stanford University, CA
- 2019 Ascites, Hepatorenal Syndrome, Hepatic Encephalopathy
GI Board Review, Stanford University, CA
- 2020 Hepatology Research Update
Digestive Disease Conference, Stanford University, CA
- 2020 GI and Liver Manifestations of COVID-19
Grand Rounds, Department of Medicine, Stanford University, CA
- 2020 Liver Masses and Tumors
GI Board Review, Stanford University, CA
- 2020 Functional Determinants of Tumor Dormancy
Stanford GI Division Research Seminar Series

REGIONAL INVITED PRESENTATIONS/TALKS

- 2017 Genomic Landscape of HCC/ Research Symposium
University of California, San Francisco
San Francisco, CA
- 2018 Genomics of Liver Cancer- Lessons from TCGA/ Grand Rounds
University of California, Davis
Davis, CA
- 2018 Liver Masses/ CME Talk
Northern California Society of Clinical Gastroenterology (NCSCG)
San Francisco, CA
- 2019 Management of Liver Cancer/ CME Talk
Northern California Society of Clinical Gastroenterology (NCSCG)
San Francisco, CA

- 2019 Case Studies in Multidisciplinary Management of Liver Cancer/Panelist
American Liver Foundation
San Francisco, CA
- 2019 Translational Research in Liver Cancer/ Grand Rounds
Hepatology Grand Rounds. California Pacific Medical Center
San Francisco, CA
- 2020 COVID-19 in Liver Diseases
Northern California Society of Clinical Gastroenterology (NCSCG)
San Francisco, CA

NATIONAL INVITED PRESENTATIONS/TALKS

- 2015 Moderator. Mixed Cholangiocarcinoma and Hepatocellular carcinoma Session.
American Association of the Study of Liver Diseases (AASLD Conference)
San Francisco, CA
- 2015 Moderator. Trainee and Young GI Sponsored Symposium
Digestive Diseases Week (DDW)
San Diego, CA
- 2017 How to engage in Professional Societies
American Gastroenterology Association (AGA) Regional Practice Workshop
Palo Alto, CA
- 2018 STATE OF THE ART LECTURE III: Hepatocellular carcinoma: Progress in
Pathogenesis and Management.
Emerging Topics in Liver Disease. Houston Methodist Hospital.
Houston, TX
- 2018 Glycoproteomics in Liver Cancer
American College of Gastroenterology Research Committee.
Philadelphia, PA
- 2019 How do cancer cells communicate with the host
Annual Biomedical Research Conference for Minority Students (ABRCMS)
Anaheim, CA.
- 2020 Moderator. Leveraging Big Data to Predict and Diagnose Cancer Treatment.
(Invited) Digestive Diseases Week (DDW)
Chicago, IL
- 2020 Moderator. Meet the Investigator Luncheon.
(Invited) Digestive Diseases Week (DDW)
Chicago, IL

2021 Recent Advanced in the Management of Liver Cancer
Chronic Liver Disease Foundation HCC ECHO CME series
Webinar

INTERNATIONAL INVITED PRESENTATIONS

2017 Management of Hepatocellular carcinoma
Manipal Hospital Grand Rounds
Bangalore, India

2020 Translational Research in Liver Cancer
Institute of Liver and Biliary Sciences
New Delhi, India

2020 HCC surveillance and therapy
Joint symposium AASLD and Japan Society of Hepatology J-DDW
Kobe, Japan

2021 Hepatobiliary Cancers: Pathobiology and Translational Advances
(Invited) Keystone Symposium
Vancouver, Canada

LICENSURE AND BOARD CERTIFICATIONS

2012 Certification, Internal Medicine, American Board of Internal Medicine

2015 Certification, Gastroenterology and Hepatology, American Board of Internal Medicine

2015 California State Medical License

PRACTICE ACTIVITIES

2016-2019	Inpatient Care	Transplant and General Hepatology, Stanford Hospital and Clinics	Two weeks per year
2016-2020	Ambulatory Care	General Hepatology, Stanford Hospital and Clinics	One half-day session per week
2016-2020	Ambulatory Care	Transplant Hepatology, Stanford Hospital and Clinics	Two half-day sessions per month
2016-2020	Ambulatory Care	GI Endoscopy, Stanford Hospital and Clinics	One half-day session per month

RECOGNITION AND NEWS

2014	First authored <i>Hepatology</i> manuscript	Recognized by Faculty of 1000 (F1000Prime) as being of special significance in its field
2014	First authored <i>Hepatology</i> manuscript	Featured in MDLinx Website as an article of importance
2017	First Authored manuscript in <i>Oncotarget</i>	Recognized as Priority manuscript by the editors at Oncotarget
2017	Publicity for the article in <i>Cell</i> for which I am one of the lead manuscript coordinators	Baylor College of Medicine News
2020	First authored paper in <i>eLife</i>	Featured on the cover
2020	First authored paper in <i>eLife</i>	Featured in MedicalXpress, EurekAlert/AAAS, Technology Networks, Clinical OMICS News, Medical Life Sciences. Highlighted on Cover of <i>eLife</i>
2021	Multiple manuscripts on COVID-19 and liver disease	Highlighted in Healio Highlighted in top 10 papers covidreference.com
2021	Invited to speak at the Moderna Vaccine Public hearing	FDA, USA

BIBLIOGRAPHY (Reverse chronology)

A. PEER REVIEWED ORIGINAL MANUSCRIPTS ORCID- 0000-0001-8819-7511

1. Adeniji N, Carr RM, Aby ES, Catana AM, Wegermann K, **Dhanasekaran R**. Socioeconomic Factors Contribute to the Higher Risk of COVID-19 in Racial and Ethnic Minorities with Chronic Liver Diseases (CLD) [Internet]. *Gastroenterology*. 2020. Available from: <http://dx.doi.org/10.1053/j.gastro.2020.11.035>
2. Adeniji N, Arjunan V, Prabhakar V, Tulu Z, Kambham N, Ahmed A, Kwo P, **Dhanasekaran R**. Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-Transplant Clinical Outcome. (2020). *Clinical Transplantation*. <https://doi.org/10.1111/ctr.14128>
3. Marjot, T, Moon, AM, Cook, JA, Abd-El salam, S, Aloman, C, Armstrong, MJ, Pose, E, Brenner, EJ, Cargill, T, Catana, MA, **Dhanasekaran, R***, Eshraghian, A, García-Juárez, I, Gill, US, Jones, PD, Kennedy, J, Marshall, A, Matthews, C, Mells, G, Mercer C, Perumalswami PV, Avitabile E, Qi X, Su F, Ufere NN, Wong Y, Zheng M, Barnes E, Barritt V AS, Webb, G. J. (2020). Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. In *Journal of Hepatology*. <https://doi.org/10.1016/j.jhep.2020.09.024>

**Acquisition of Data, Critical revision of manuscript, Study Design*

4. Krishnan M, Rajan A, Arjunan V, Park J, Marques F, Bermudez A, Girvan O, Hoang N, Yin J, Nguyen M, Kothary N, Pitteri S, Felsher D, **Dhanasekaran R**. Genomic Analysis of Vascular Invasion in Hepatocellular Carcinoma (HCC) Reveals Molecular Drivers and Predictive Biomarkers. Accepted in *Hepatology*. October 2020.
5. Rabiee, A*, Sadowski, B*, Adeniji N, Perumalswami P, Nguyen, V, Moghe, A, Latt, N, Kumar S, Aloman, C, Catana, AM, Bloom, PP, Chavin, K, Carr, RM, Dunn, W, Chen, V, Aby, ES, Debes JD, **Dhanasekaran, R**. Liver Injury in Liver Transplant Recipients with Coronavirus Disease 2019 (COVID-19): US Multicenter Experience. Accepted in *Hepatology* September 2020.

** Co-First Authors*

6. Kim D*, Adeniji N*, Latt N, Kumar S, Bloom PP, Aby ES, Perumalswami P, Roytman M, Li M, Vogel AS, Catana AM, Wegermann K, Carr RM, Aloman C, Chen V, Rabiee A, Sadowski B, Nguyen V, Dunn W, Chavin K, Zhou K, Lizaola-Mayo B, Moghe A, Debes JD, Lee TH, Branch A, Viveiros K, Chan W, Chascsa D, Kwo P, **Dhanasekaran R**. "Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-Center Study." *Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association*, September 2020. <https://doi.org/10.1016/j.cgh.2020.09.027>

** Co-First Authors*

7. Webb, GJ, Marjot T, Cook JA, Aloman C, Armstrong MA, Brenner EJ, Catana M, Cargill T, **Dhanasekaran R***, Garcia-Juarez I, Hagstrom H, Kennedy J, Marshall A, Masson, S, Mercer C, Perumalswami P, Ruiz I, Thaker S, Ufere N, Barnes E, Barritt IV, A, Moon AM . Outcomes Following SARS-CoV-2 Infection in Liver Transplant Recipients: An International Registry Study. *The Lancet. Gastroenterology & Hepatology*, August. [https://doi.org/10.1016/S2468-1253\(20\)30271-5](https://doi.org/10.1016/S2468-1253(20)30271-5).

** Acquisition of Data, Critical revision of manuscript, Study Design*

8. **Dhanasekaran R**, Park J, Adams S, Bellovin, D, Gabay M, Anand Rajan KD, Yevtodiyeenko A, Fernando H, Arzeno J, Arjunan V, Gryanzov S and Felsher DW. MYC Antisense Oligonucleotide Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of Hepatocellular and Renal Cell Carcinoma. *Molecular Therapy- Nucleic Acids*. 2020 Sep 4;21:850–9. <https://doi.org/10.1016/j.omtn.2020.07.008>.
9. Arjunan V, Hansen A, Deutzmann A, Sze DY, **Dhanasekaran R**. Spontaneous Regression of HCC-When the Immune System Stands Up to Cancer. *Hepatology*. 2020. <http://dx.doi.org/10.1002/hep.31489>
10. Moon AM, Webb GJ, Aloman C, Armstrong M, Cargill T, **Dhanasekaran R***, Genesca J, Gull U, James TW, Jones PD, Marshall A, Meils G, Perumalswami P, Qi X, Su F, Ufere N, Barnes E, Barritt AS, Marjot T. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. *J. Hepatol.* (2020) doi:10.1016/j.jhep.2020.05.013.

** Acquisition of Data, Critical revision of manuscript, Study Design*

11. Swaminathan S, Hansen A, Heftdal LD, **Dhanasekaran R***, Deutzmann A, Liefwalker DF, Horton C, Mosley A, Liebersbach M, Maecker H, Felsher DW. MYC Functions as a Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies. *Nat Commun*. 2020 Jun. doi:10.1038/s41467-020-16447-75;11(1):2860.

** Acquisition of Data, Analysis and Interpretation of data, Critical revision of manuscript*

12. Carr RM, Romecin Duran PA, Tolosa EJ, Ma C, Oseini AM, Moser CD, Banini BA, Huang J, Asumda F, **Dhanasekaran R***, Graham RP, Toruner MD, Safgren SL, Almada LL, Wang S, Patnaik MM, Roberts LR, Fernandez-Zapico ME. The extracellular sulfatase SULF2 promotes liver

- tumorigenesis by stimulating assembly of a promoter looping GLI1-STAT3 transcriptional complex. *J Biol Chem*. 2020 Jan 27;. doi: 10.1074/jbc.RA119.011146. PubMed PMID: 31988246.
- * Acquisition of Data, Analysis and Interpretation of data, Critical revision of manuscript*
13. **Dhanasekaran R***, Baylot V*, Kim M, Kuruvilla S, Bellovin DI, Adeniji N, Rajan Kd A, Lai I, Gabay M, Tong L, Krishnan M, Park J, Hu T, Barbhuiya MA, Gentles AJ, Kannan K, Tran PT, Felsher DW. MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. *Elife*. 2020 Jan 14;9. doi: 10.7554/eLife.50731. PubMed PMID: 31933479; PubMed Central PMCID: PMC6959993.
14. Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, **Dhanasekaran R***, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. *Gastroenterology*. 2019 Nov;157(5):1253-1263.e2. doi: 10.1053/j.gastro.2019.07.040. Epub 2019 Jul 30. PubMed PMID: 31374215; PubMed Central PMCID: PMC6815711.
- * Acquisition of Data, Critical revision of manuscript*
15. Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette C, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, **Dhanasekaran R***, Odewole M, Kagan S, Marrero JA, Singal AG. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients with Hepatocellular Carcinoma. *Clin Gastroenterol Hepatol*. 2019 Jul 26;. doi: 10.1016/j.cgh.2019.07.042. [Epub ahead of print] PubMed PMID: 31357028.
- * Acquisition of Data, Critical revision of manuscript*
16. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, **Dhanasekaran R***, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Nouredine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. *Gastroenterology*. 2019 May;156(6):1683-1692.e1. doi: 10.1053/j.gastro.2019.01.027. Epub 2019 Jan 18. PubMed PMID: 30660729; PubMed Central PMCID: PMC6598433.
- * Acquisition of Data, Study Design, Critical revision of manuscript*
17. Lai I, Swaminathan S, Baylot V, Mosley A, **Dhanasekaran R***, Gabay M, Felsher DW. Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma. *J Immunother Cancer*. 2018 Nov 20;6(1):125. doi: 10.1186/s40425-018-0431-x. PubMed PMID: 30458889; PubMed Central PMCID: PMC6247677.
- * Acquisition of Data, Analysis and Interpretation of data, Critical revision of manuscript*
18. Guo P, Wang Y, Dai C, Tao C, Wu F, Xie X, Yu H, Zhu Q, Li J, Ye L, Yu F, Shan Y, Yu Z, **Dhanasekaran R***, Zheng R, Chen G. Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt/ β -catenin-induced FGF18 expression in hepatocellular carcinoma. *Oncogene*. 2018

Mar;37(9):1220-1236. doi: 10.1038/s41388-017-0017-y. Epub 2017 Dec 15. PubMed PMID: 29242604.

** Critical revision of manuscript*

19. Rizvi S, Fischbach S, Bronk S, Hirsova P, Krishnan A, **Dhanasekaran R***, Smadbeck J, Smoot R, Vasmatis G, Gores G. Yap-associated Chromosomal Instability And Cholangiocarcinoma In Mice. *Oncotarget*. 2018 Jan 19;9(5):5892-5905. doi: 10.18632/oncotarget.23638. eCollection 2018 Jan 19. PubMed PMID: 29464042; PubMed Central PMCID: PMC5814182

** Acquisition of Data, Analysis and Interpretation of data*

20. **Dhanasekaran R**, Gabay-Ryan, M, Baylot V, Lai I, Mosley A, Huang X, Zabudoff S, Li J, Kaimal V, Karmali P, Felsher D. Anti-miR-17 Therapy Delays Tumorigenesis in MYC-driven Hepatocellular Carcinoma (HCC). *Oncotarget*. 2018 Jan 19;9(5):5517-5528. doi: 10.18632/oncotarget.22342. eCollection 2018 Jan 19. PubMed PMID: 29464015; PubMed Central PMCID: PMC5814155.

21. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. *Cell*. 2017 Jun 15;169(7):1327-1341.e23. doi: 10.1016/j.cell.2017.05.046. PubMed PMID: 28622513; PubMed Central PMCID: PMC5680778. **Dhanasekaran R***- Manuscript Coordinator

** Acquisition of Data, Analysis and Interpretation of data, Drafting the manuscript, Statistical analysis*

22. Xing M, Sakaria S, **Dhanasekaran R***, Parekh S, Spivey J, Knechtle SJ, Zhang D, Kim HS. Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma. *Cardiovasc Intervent Radiol*. 2017 Mar;40(3):410-420. doi: 10.1007/s00270-016-1505-0. Epub 2016 Nov 29. PubMed PMID: 27900445.

** Acquisition of Data, Critical revision of manuscript*

23. Chen G*, Nakamura I*, **Dhanasekaran R***, Iguchi E*, Tolosa E*, Romecin-Duran P, Vera R, Almada L, Miamen A, Chaiteerakij R, Zhou M, Asiedu M, Moser C, Han S, Hu C, Banini B, Oseini A, Chen Y, Fang Y, Yang D, Shaleh H, Wang S, Wu, Song D, Lee JS, Thorgeirsson S, Chevet E, Shah V, Fernandez-Zapico M, Roberts LR. Transcriptional induction of Periostin by a Sulfatase 2-TGFβ1-SMAD signaling axis mediates tumor angiogenesis in hepatocellular carcinoma. *Cancer Res*. 2017 Feb 1;77(3):632-645. doi: 10.1158/0008-5472.CAN-15-2556. Epub 2016 Nov 21. PubMed PMID: 27872089; PubMed Central PMCID: PMC5429157.

** Co-first authors*

** Acquisition of Data, Analysis and Interpretation of data, Drafting the manuscript, Statistical analysis*

24. Xing M, Prajapati HJ, **Dhanasekaran R***, Lawson DH, Kokabi N, Eaton BR, Kim HS. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study. *Am J Clin Oncol*. 2017 Feb;40(1):27-34. doi: 10.1097/COC.000000000000109. PubMed PMID: 25089529.

25. **Dhanasekaran R**, Sanchez W, Charlton M. Response to Fibrosis progression in patients treated for hepatitis C recurrence. *Liver Int*. 2015 Dec;35(12):2625. doi: 10.1111/liv.12969. PubMed PMID: 26386267.

26. **Dhanasekaran R**, Sanchez W, Mounajjed T, Wiesner RH, Watt KD, Charlton MR. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. *Liver Int*. 2015 Nov;35(11):2433-41. doi: 10.1111/liv.12890. Epub 2015 Jul 1. PubMed PMID: 26058570.

27. Tu, K, Li, J, Verma, VK., Liu, C, Billadeau, DD., Lamprecht, G, Xiang, X, Guo, L, **Dhanasekaran, R***, Roberts, LR., Shah, VH., Kang, N. Vasodilator-stimulated phosphoprotein promotes activation of hepatic stellate cells by regulating Rab11-dependent plasma membrane targeting of transforming growth factor beta receptors. *Hepatology*. 2015 Jan;61(1):361-74. doi: 10.1002/hep.27251. Epub 2014 Sep 19. PubMed PMID: 24917558; PubMed Central PMCID: PMC4262723.

* *Acquisition of Data, Analysis and Interpretation of data*

28. **Dhanasekaran, R**, Nakamura, I, Hu, C, Chen, G, Oseini, AM, Seven, ES, Miamen, A, Moser, CD, Zhou, W, van Kuppevelt, TH. vanDeursen, J, Mounajjed, T, Fernandez-Zapico, ME, Roberts, LR. Activation of the TGF β /SMAD transcriptional pathway underlies a novel tumor promoting role of sulfatase1 in hepatocellular carcinoma. *Hepatology*. 2015 Apr;61(4):1269-83. doi: 10.1002/hep.27658. Epub 2015 Feb 13. PubMed PMID: 25503294; PubMed Central PMCID: PMC4376661.
29. **Dhanasekaran R**, Kim HS. Response to Houlihan et al. *Am J Gastroenterol*. 2013 Nov;108(11):1807. doi: 10.1038/ajg.2013.300. PubMed PMID: 24192955.
30. **Dhanasekaran R**, Hemming AW, Zendejas I, George T, Nelson DR, Soldevila-Pico C, Firpi RJ, Morelli G, Clark V, Cabrera R. Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. *Oncol Rep*. 2013 Apr;29(4):1259-67. doi: 10.3892/or.2013.2290. Epub 2013 Feb 18. PubMed PMID: 23426976; PubMed Central PMCID: PMC3621732.
31. **Dhanasekaran R**, Pannu DS, Limaye A, Zendejas I, Firpi RJ, Soldevila-Pico C, Morelli G, Clark VC, Suman A, Nelson DR, Cabrera R. Incidentally Discovered HCC (iHCC) in Explant Liver-Histopathologic Features and Clinical Outcome. *Journal of Cancer Therapy* 4, 394-398.
32. **Dhanasekaran R**, Khanna V, Kooby DA, Kauh JS, Carew JD, Kim HS. Chemoembolization Combined with RFA for HCC: Survival Benefits and Tumor Treatment Response. *Journal of Cancer Therapy* 4, 493-499
33. Michaels AJ, **Dhanasekaran R***, Foley DP, Alkhasawneh A, Dixon L, Soldevila-Pico C, Morelli G, Cabrera R, Clark VC, Firpi RJ. Hepatic preservation injury: severity of hepatitis C recurrence and survival after liver transplantation. *Dig Dis Sci*. 2013 May;58(5):1403-9. doi: 10.1007/s10620-012-2521-9. Epub 2013 Jan 10. PubMed PMID: 23306846; PubMed Central PMCID: PMC3665404.

* *Analysis and Interpretation of data, Drafting the manuscript, Statistical analysis*

34. Prajapati HJ, **Dhanasekaran R***, El-Rayes BF, Kauh JS, Maithel SK, Chen Z, Kim HS. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. *J Vasc Interv Radiol*. 2013 Mar;24(3):307-15. doi: 10.1016/j.jvir.2012.11.026. Epub 2013 Jan 29. PubMed PMID: 23375519.

* *Acquisition of Data, Critical revision of manuscript*

35. **Dhanasekaran R**, Owens V, Sanchez W. Chinese skullcap in move free arthritis supplement causes drug induced liver injury and pulmonary infiltrates. *Case Reports Hepatol*. 2013;2013:965092. doi: 10.1155/2013/965092. Epub 2013 Apr 14. PubMed PMID: 25431706; PubMed Central PMCID: PMC4238172.
36. **Dhanasekaran R**, Gonzales P, West J, Subramanian R, Parekh S, Spivey J, Reshamwala P, Martin LG, Kim HS. Predictors of early mortality post transjugular intrahepatic portosystemic shunts and the role of hepatic venous pressure gradient. *Gastrointestinal Intervention* 1(1): 63-68.
37. Gonzales, P., **Dhanasekaran R**, West J, Subramanian R, Parekh S, Spivey J, Reshamwala P, Martin LG, Kim HS. (2012). "Influence of transjugular intrahepatic portosystemic shunt in patients awaiting orthotopic liver transplant on post-transplant outcome." *Gastrointestinal Intervention* 1(1): 69-73.

* *Acquisition of Data, Critical revision of manuscript*

38. **Dhanasekaran R**, Hemming A, Salazar A, and Cabrera R, "Rare Case of Adult Undifferentiated (Embryonal) Sarcoma of the Liver Treated with Liver Transplantation: Excellent Long-Term Survival," *Case Reports Hepatol*. 2012;2012:519741. doi: 10.1155/2012/519741. Epub 2012 Sep 27. PubMed PMID: 25374706; PubMed Central PMCID: PMC4208439.

39. Piduru SM, Schuster DM, Barron BJ, **Dhanasekaran R**, Lawson DH, Kim HS. Prognostic value of ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization. *J Vasc Interv Radiol*. 2012 Jul;23(7):943-8. doi: 10.1016/j.jvir.2012.04.010. Epub 2012 May 19. PubMed PMID: 22609292.
* *Acquisition of Data, Statistical analysis, Critical revision of manuscript*
40. Clark VC, **Dhanasekaran R**, Brantly M, Rouhani F, Schreck P, Nelson DR. Liver test results do not identify liver disease in adults with α (1)-antitrypsin deficiency. *Clin Gastroenterol Hepatol*. 2012 Nov;10(11):1278-83. doi: 10.1016/j.cgh.2012.07.007. Epub 2012 Jul 24. PubMed PMID: 22835581; PubMed Central PMCID: PMC3482934.
* *Acquisition of Data, Statistical analysis, Critical revision of manuscript*
41. Farris AB 3rd, Dursun N, **Dhanasekaran R**, Coban I, McIntosh EB, Adsay NV, Kim HS. Tumoral and angiogenesis factors in hepatocellular carcinoma after locoregional therapy. *Pathol Res Pract*. 2012 Jan 15;208(1):15-21. doi: 10.1016/j.prp.2011.10.005. Epub 2011 Nov 15. PubMed PMID: 22088254.
* *Acquisition of Data, Critical revision of manuscript*
42. Cabrera R, **Dhanasekaran R**, Caridi J, Soldevila-Pico C, Morelli G, Clark VC, Nelson DR, Firpi RJ. The Impact of Transarterial Therapy in Hepatitis C Related Hepatocellular Carcinoma on Long Term Outcomes after Liver Transplantation. *Am J Clin Oncol*. 2012 Aug;35(4):345-50. doi: 10.1097/COC.0b013e31821631f6. PubMed PMID: 21552101; PubMed Central PMCID: PMC3155640.
* *Acquisition of Data, Statistical analysis, Critical revision of manuscript*
43. **Dhanasekaran R**, West J, Gonzales PC, Subramanian R, Parekh S, Spivey JR, Martin LG, Kim HS. Transjugular Intrahepatic Portosystemic Shunt for Symptomatic Refractory Hepatic Hydrothorax. *Am J Gastroenterol*. 2010 Mar;105(3):635-41. doi: 10.1038/ajg.2009.634. Epub 2009 Nov 10. PubMed PMID: 19904245.
44. **Dhanasekaran R**, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS.. Comparison of Transarterial Chemoembolization with Doxorubicin Eluting Beads vs. Conventional Chemoembolization for Unresectable Hepatocellular Carcinoma. *J Surg Oncol*. 2010 May 1;101(6):476-80. doi: 10.1002/jso.21522. PubMed PMID: 20213741.
45. **Dhanasekaran R**, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Prognostic Factors for Survival in Patients with Unresectable Hepatocellular Carcinoma Undergoing Chemoembolization with Doxorubicin Drug Eluting Beads: A Preliminary Study. *HPB (Oxford)*. 2010 Apr;12(3):174-80. doi: 10.1111/j.1477-2574.2009.00138.x. PubMed PMID: 20590884; PubMed Central PMCID: PMC2889269.
46. **Dhanasekaran R**, Khanna V, Kooby DA, Spivey JR, Parekh S, Knechtle SJ, Carew JD, Kim HS. The Effectiveness of Locoregional Therapies versus Supportive Care in Maintaining Survival within the Milan Criteria in Patients with Hepatocellular Carcinoma. *J Vasc Interv Radiol*. 2010 Aug;21(8):1197-204; quiz 204. doi: 10.1016/j.jvir.2010.04.018. PubMed PMID: 20656222.

B. SUBMITTED WORK

1. Deutzmann A, Li Y, Sullivan DK, **Dhanasekaran R**, Li W, Tong L, Mahauad-Fernandez WD, Bell Mosley A, Felsher DW. Genome-wide CRISPR Essentiality Screen Identifies Nuclear to Cytoplasmic Transport as a Druggable Dependency in MYC-Driven Cancer. *Revise and Resubmit for Nature Communications*.

C. PEER REVIEWED INVITED REVIEW ARTICLES AND EDITORIALS

1. **Dhanasekaran R.** Deciphering Tumor Heterogeneity in Hepatocellular Carcinoma (HCC) - Multi-omic and Singulomic Approaches. Accepted Seminars in Liver Disease.
2. Adeniji N, **Dhanasekaran R.** Genomic Landscape of HCC [Internet]. Current Hepatology Reports. 2020. Available from: <http://dx.doi.org/10.1007/s11901-020-00553-7>
3. Kapuria, D, Bollipo S, Rabiee A, Yakov GB, Kumar G, Siau K, Lee H, Congly S, Turnes J, **Dhanasekaran R**, Lui RN. Roadmap to Resuming Care for Liver Diseases after COVID-19. Journal of Gastroenterology and Hepatology. 2020. <https://doi.org/10.1111/jgh.15178>.
4. Bollipo S, Kapuria D, Rabiee A, Yakov GB, Lui R, Lee HW, Kumar G, Siau K, Turnes J, **Dhanasekaran R.** One World, One Pandemic, Many Guidelines- Management of Liver Diseases During COVID-19. Accepted Gut Apr 2020.
5. **Dhanasekaran R**, Felsher DW. A Tale of Two Complications of Obesity: NASH and Hepatocellular Carcinoma. Hepatology. 2019 Sep;70(3):1056-1058. doi: 10.1002/hep.30649. Epub 2019 May 27. PubMed PMID: 30958566; PubMed Central PMCID: PMC6717523.
6. **Dhanasekaran R**, Nault JC, Roberts LR, Zucman-Rossi J. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology. 2019 Jan;156(2):492-509. doi: 10.1053/j.gastro.2018.11.001. Epub 2018 Nov 4. Review. PubMed PMID: 30404026; PubMed Central PMCID: PMC6340723.
7. **Dhanasekaran R**, Kwo PY. The Liver in Oncology. Clin Liver Dis. 2017 Nov;21(4):697-707. doi: 10.1016/j.cld.2017.06.003. Epub 2017 Jul 26. Review. PubMed PMID: 28987257.
8. **Dhanasekaran R.** Management of Immunosuppression in Liver Transplantation. Clin Liver Dis. 2017 May;21(2):337-353. doi: 10.1016/j.cld.2016.12.007. Review. PubMed PMID: 28364817.
9. **Dhanasekaran R**, Bandoh S, Roberts LR. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Res. 2016;5. doi: 10.12688/f1000research.6946.1. eCollection 2016. Review. PubMed PMID: 27239288; PubMed Central PMCID: PMC4870992.
10. **Dhanasekaran R**, Venkatesh SK, Torbenson MS, Roberts LR. Clinical implications of basic research in hepatocellular carcinoma. J Hepatol. 2016 Mar;64(3):736-45. doi: 10.1016/j.jhep.2015.09.008. Epub 2015 Oct 9. Review. PubMed PMID: 26450813; PubMed Central PMCID: PMC5039166.
11. **Dhanasekaran R**, Talwalkar JA. Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma. Curr Gastroenterol Rep. 2015 Sep;17(9):34. doi: 10.1007/s11894-015-0459-8. Review. PubMed PMID: 26238927.
12. **Dhanasekaran R**, Heimbach, JK. Liver Transplantation for Hepatocellular Carcinoma. Current Transplantation Reports. 2014. doi:10.1007/s40472-014-0028-3.
13. **Dhanasekaran R**, Firpi RJ. Challenges of recurrent hepatitis C in liver transplant patients. World J Gastroenterol. 2014 Apr 7;20(13):3391-400. doi: 10.3748/wjg.v20.i13.3391. Review. PubMed PMID: 24707122; PubMed Central PMCID: PMC3974506.
14. **Dhanasekaran R**, Toskes PP. Pancrelipase for pancreatic disorders: An update. Drugs Today (Barc). 2010 Nov;46(11):855-66. doi: 10.1358/dot.2010.46.11.1541553. Review. PubMed PMID: 21225024.
15. **Dhanasekaran R**, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012 May 8;4:19-37. doi: 10.2147/HMER.S16316. Review. PubMed PMID: 24367230; PubMed Central PMCID: PMC3846594.

D. PEER REVIEWED BOOK CHAPTERS

1. **Dhanasekaran R**, Heimbach JK, Roberts LR (2016) Textbook Chapter- Primary Carcinoma of the Liver. Book- Practical Gastroenterology and Hepatology. Book Editor(s): Michael B. Wallace Bashar A. Aqel Keith D. Lindor Kenneth R. Devault. doi.org/10.1002/9781119127437.ch89
2. **Dhanasekaran R**, Cabrera R. (2012) Emerging therapies in hepatocellular carcinoma. Textbook Chapter- Primary Liver Cancer. Surveillance, Diagnosis and Treatment. 2012. **Editors:** Nancy Reau, Fred Poordad. Print ISBN 978-1-61779-862-7. Publisher- Humana.
3. **Dhanasekaran R**, Williams RS, Kim HS. (2010). Contrast Media: Issues for the Interventionalist. In Waybill PN, Brown T (Ed.), Patient Care in Vascular and Interventional Radiology (pp. -). Fairfax, VA. Society of Interventional Radiology.

E. SCHOLARSHIP AS PART OF THE CANCER GENOME ATLAS (TCGA) RESEARCH NETWORK

** Authorship granted on the following manuscripts as a member of the TCGA Research Network (one of 725 members who have contributed samples and/or participated in analysis working groups).*

1. The Immune Landscape of Cancer. Immunity. 2019 Aug 20;51(2):411-412. doi: 10.1016/j.immuni.2019.08.004. No abstract available. PubMed [citation] PMID: 31433971
2. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. Cell Syst. 2018 Oct 24;7(4):422-437.e7. doi:10.1016/j.cels.2018.08.010. Epub 2018 Sep 26. PubMed [citation] PMID: 30268436, PMCID: PMC6370347
3. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018 Aug 9;174(4):1034-1035. doi: 10.1016/j.cell.2018.07.034. No abstract available. PubMed [citation] PMID: 30096302
4. Rättsch G. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell. 2018 Aug 13;34(2):211-224.e6. doi: 10.1016/j.ccell.2018.07.001. Epub 2018 Aug 2. PubMed [citation] PMID: 30078747
5. The Immune Landscape of Cancer. Immunity. 2018 Apr 17;48(4):812-830.e14. doi: 10.1016/j.immuni.2018.03.023. Epub 2018 Apr 5. Erratum in: Immunity. 2019 Aug 20;51(2):411-412. PubMed [citation] PMID: 29628290, PMCID: PMC5982584
6. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018 Apr 5;173(2):371-385.e18. doi: 10.1016/j.cell.2018.02.060.
7. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018 Apr 5;173(2):321-337.e10. doi: 10.1016/j.cell.2018.03.035. PubMed [citation] PMID:29625050, PMCID: PMC6070353
8. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018 Apr 5;173(2):400-416.e11. doi: 10.1016/j.cell.2018.02.052. PubMed [citation] PMID: 29625055, PMCID: PMC6066282
9. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell. 2018 Apr 5;173(2):305-320.e10. doi: 10.1016/j.cell.2018.03.033. PubMed [citation] PMID: 29625049, PMCID: PMC5916814
10. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell. 2018 Apr 5;173(2):338-354.e15. doi: 10.1016/j.cell.2018.03.034. PubMed [citation] PMID: 29625051, PMCID: PMC5902191
11. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell. 2018 Apr 5;173(2):355-370.e14. doi: 10.1016/j.cell.2018.03.039. PubMed [citation] PMID: 29625052, PMCID: PMC5949147

12. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. *Cell*. 2018 Apr 5;173(2):386-399.e12. doi: 10.1016/j.cell.2018.03.027. PubMed [citation] PMID: 29625054, PMCID: PMC5890960
13. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. *Cell*. 2018 Apr 5;173(2):291-304.e6. doi: 10.1016/j.cell.2018.03.022. PubMed [citation] PMID: 29625048, PMCID: PMC5957518
14. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. *Cancer Cell*. 2018 Apr 9;33(4):706-720.e9. doi: 10.1016/j.ccell.2018.03.006. Epub 2018 Apr 2. PubMed [citation] PMID: 29622465, PMCID: PMC6143179
15. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. *Cancer Cell*. 2018 Apr 9;33(4):690-705.e9. doi: 10.1016/j.ccell.2018.03.014. Epub 2018 Apr 2. PubMed [citation] PMID: 29622464, PMCID: PMC5959730
16. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. *Cancer Cell*. 2018 Apr 9;33(4):676-689.e3. doi: 10.1016/j.ccell.2018.03.007. Epub 2018 Apr 2. PubMed [citation] PMID: 29622463, PMCID: PMC6028190
17. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. *Cancer Cell*. 2018 Apr 9;33(4):721-735.e8. doi: 10.1016/j.ccell.2018.03.010. Epub 2018 Apr 2. PubMed [citation] PMID: 29622466, PMCID: PMC5966039
18. Systematic Analysis of Splice-Site-Creating Mutations in Cancer. *Cell Rep*. 2018 Apr 3;23(1):270-281.e3. doi: 10.1016/j.celrep.2018.03.052. PubMed [citation] PMID: 29617666, PMCID: PMC6055527
19. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. *Cell Rep*. 2018 Apr 3;23(1):282-296.e4. doi: 10.1016/j.celrep.2018.01.088. PubMed [citation] PMID: 29617667, PMCID: PMC5933844
20. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. *Cell Rep*. 2018 Apr 3;23(1):213-226.e3. doi: 10.1016/j.celrep.2018.03.047. PubMed [citation] PMID: 29617661, PMCID: PMC5916807
21. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. *Cell Rep*. 2018 Apr 3;23(1):227-238.e3. doi: 10.1016/j.celrep.2018.03.050. PubMed [citation] PMID: 29617662, PMCID: PMC5916809
22. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. *Cell Rep*. 2018 Apr 3;23(1):181-193.e7. doi: 10.1016/j.celrep.2018.03.086. PubMed [citation] PMID: 29617659, PMCID: PMC5943714
23. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Rep*. 2018 Apr 3;23(1):313-326.e5. doi:10.1016/j.celrep.2018.03.075. Erratum in: *Cell Rep*. 2018 Jun 19;23(12):3698. PubMed [citation] PMID: 29617669, PMCID: PMC6075733
24. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. *Cell Rep*. 2018 Apr 3;23(1):239-254.e6. doi: 10.1016/j.celrep.2018.03.076. PubMed [citation] PMID: 29617664, PMCID: PMC5961503
25. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. *Cell Rep*. 2018 Apr 3;23(1):297-312.e12. doi: 10.1016/j.celrep.2018.03.064. PubMed [citation] PMID: 29617668, PMCID: PMC5906131
26. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. *Cell Rep*. 2018 Apr 3;23(1):194-212.e6. doi: 10.1016/j.celrep.2018.03.063. PubMed [citation] PMID: 29617660, PMCID: PMC6002769

27. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. *Cell Rep.* 2018 Apr 3;23(1):255-269.e4. doi: 10.1016/j.celrep.2018.03.077. PubMed [citation] PMID: 29617665, PMCID: PMC5916795
28. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. *Cell Rep.* 2018 Apr 3;23(1):172-180.e3. doi: 10.1016/j.celrep.2018.03.046. PubMed [citation] PMID: 29617658, PMCID: PMC5918694
29. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. *Cell Syst.* 2018 Mar 28;6(3):282-300.e2. doi: 10.1016/j.cels.2018.03.003. PubMed [citation] PMID: 29596783, PMCID: PMC5892207
30. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. *Cell Syst.* 2018 Mar 28;6(3):271-281.e7. doi: 10.1016/j.cels.2018.03.002. PubMed [citation] PMID: 29596782, PMCID: PMC6075717

F. INVITED SOCIAL MEDIA POSTS

1. AASLD Blog. Why I use Social media. 2019.
<https://www.aasld.org/membership/member-resources/social-media-essentials/renu-dhanasekaran-m-d>
2. AGA Perspectives. Updates from the AGA Young Delegates Program. 2017.
http://agaperspectives.gastro.org/author/ssingh/#.XRmXltNKi_s
3. AGA DDW Blog. Tips for Fellows: How to effectively Effectively Navigate DDW. 2015.
<http://ddwblog.org/2015/02/tips-for-fellows-how-to-effectively-navigate-ddw/>
4. Becker's GI and Endoscopy. Young gastroenterologists: the essential skills to thrive in healthcare today. 2014.
<https://www.beckersasc.com/gastroenterology-and-endoscopy/young-gastroenterologists-the-essential-skills-to-thrive-in-healthcare-today.html>

G. SELECTED ABSTRACT PRESENTATIONS - PAST 5 YEARS

1. **AASLD 2020.** On behalf of the COLD consortium. Predictors of Clinical Outcomes in Patients with COVID-19 and chronic liver diseases. Plenary Oral Presentation.
2. **AASLD 2019.** Krishnan M, Arjunan V, Kothary N, Felsher S, **Dhanasekaran R.** Cross-Species Comprehensive Proteomic Analysis of Hepatocellular Carcinoma (HCC) to Identify Plasma Biomarkers of Vascular Invasion.
3. **AASLD 2019.** Arjunan V, Prabhakar V, Raghavan SS, Tulu Z, Kambham N, Ahmed A, Kwo PY, **Dhanasekaran R.** Clinicopathological Features of Nonalcoholic Steatohepatitis (NASH)-Related Hepatocellular Carcinoma (HCC).
4. **AASLD 2019.** Arjunan V, Prabhakar V, Raghavan SS, Tulu Z, Kambham N, Ahmed A, Kwo PY, **Dhanasekaran R.** Is it a good idea to offer transplant exception points for septuagenarians with hepatocellular carcinoma (HCC)?
5. **AASLD 2017.** **Dhanasekaran R,** Baylot V, Mosley A, Felsher D. MYC is the master switch between tumor dormancy and relapse in Hepatocellular carcinoma (HCC).
6. **AASLD 2015.** **Dhanasekaran R,** Covington K, Watt J, Cherniack AD, O'Brien DR, Lee JS, Creighton C Munzy DM, Roberts LR, Wheeler DA. Multi-platform analysis of Telomerase Reverse Transcriptase (TERT) gene alterations in Hepatocellular Carcinoma (HCC).